-
1 Comment
Pro Medicus Limited is currently in a long term uptrend where the price is trading 41.4% above its 200 day moving average.
From a valuation standpoint, the stock is 70.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.1.
Pro Medicus Limited's total revenue rose by 7.8% to $32M since the same quarter in the previous year.
Its net income has increased by 12.4% to $14M since the same quarter in the previous year.
Finally, its free cash flow grew by 89.4% to $8M since the same quarter in the previous year.
Based on the above factors, Pro Medicus Limited gets an overall score of 5/5.
Sector | Healthcare |
---|---|
ISIN | AU000000PME8 |
Exchange | AU |
CurrencyCode | AUD |
Industry | Health Information Services |
PE Ratio | 254.8 |
---|---|
Target Price | 248.952 |
Market Cap | 25B |
Dividend Yield | 0.2% |
Beta | 0.39 |
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PME.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025